111 related articles for article (PubMed ID: 22739170)
1. [Clinical study of bortezomib for treating multiple myeloma with renal impairment].
Kang Y; Zhao YY; Guo M; Yu CL; Qiao JH; Hu KX; Sun QY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):628-31. PubMed ID: 22739170
[TBL] [Abstract][Full Text] [Related]
2. [Clinical feature and efficacy of patients with multiple myeloma and renal impairment treated with bortezomib based chemotherapy].
Xu Y; An G; Deng SH; Sui WW; Feng XY; Li F; Hao M; Wang YF; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):304-8. PubMed ID: 23668201
[TBL] [Abstract][Full Text] [Related]
3. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
4. Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.
Dimopoulos MA; Roussou M; Gavriatopoulou M; Zagouri F; Migkou M; Matsouka C; Barbarousi D; Christoulas D; Primenou E; Grapsa I; Terpos E; Kastritis E
Clin Lymphoma Myeloma; 2009 Aug; 9(4):302-6. PubMed ID: 19717380
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment.
Zannetti BA; Zamagni E; Santostefano M; De Sanctis LB; Tacchetti P; Mancini E; Pantani L; Brioli A; Rizzo R; Mancuso K; Rocchi S; Pezzi A; Borsi E; Terragna C; Marzocchi G; Santoro A; Cavo M
Am J Hematol; 2015 Jul; 90(7):647-52. PubMed ID: 25858483
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.
Li J; Zhou DB; Jiao L; Duan MH; Zhang W; Zhao YQ; Shen T
Clin Lymphoma Myeloma; 2009 Oct; 9(5):394-8. PubMed ID: 19858061
[TBL] [Abstract][Full Text] [Related]
8. Clinical assessment of bortezomib for multiple myeloma in comparison with thalidomide.
Satoh M; Oguro R; Yamanaka C; Takada K; Matsuura Y; Akiba T; Aotsuka N; Tani Y; Wakita H
J Pharm Pharm Sci; 2011; 14(1):78-89. PubMed ID: 21501555
[TBL] [Abstract][Full Text] [Related]
9. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
Petrucci MT; Giraldo P; Corradini P; Teixeira A; Dimopoulos MA; Blau IW; Drach J; Angermund R; Allietta N; Broer E; Mitchell V; Bladé J
Br J Haematol; 2013 Mar; 160(5):649-59. PubMed ID: 23293914
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
Jagannath S; Barlogie B; Berenson JR; Singhal S; Alexanian R; Srkalovic G; Orlowski RZ; Richardson PG; Anderson J; Nix D; Esseltine DL; Anderson KC;
Cancer; 2005 Mar; 103(6):1195-200. PubMed ID: 15690325
[TBL] [Abstract][Full Text] [Related]
11. [Observational retrospective study to evaluate the effectiveness and safety of treatment schemes with bortezomib for multiple myeloma in our hospital].
Titos-Arcos JC; León-Villar J; de Arriba de la Fuente F; Moreno Belmonte MJ; Iranzo Fernández MD
Farm Hosp; 2012; 36(4):275-81. PubMed ID: 22115856
[TBL] [Abstract][Full Text] [Related]
12. A practical update on the use of bortezomib in the management of multiple myeloma.
San Miguel J; Bladé J; Boccadoro M; Cavenagh J; Glasmacher A; Jagannath S; Lonial S; Orlowski RZ; Sonneveld P; Ludwig H
Oncologist; 2006 Jan; 11(1):51-61. PubMed ID: 16401713
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of bortezomib in relapsed, refractory myeloma.
Richardson PG; Barlogie B; Berenson J; Singhal S; Jagannath S; Irwin D; Rajkumar SV; Srkalovic G; Alsina M; Alexanian R; Siegel D; Orlowski RZ; Kuter D; Limentani SA; Lee S; Hideshima T; Esseltine DL; Kauffman M; Adams J; Schenkein DP; Anderson KC
N Engl J Med; 2003 Jun; 348(26):2609-17. PubMed ID: 12826635
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic efficacy of bortezomib-based chemotherapy on 40 patients with multiple myeloma].
Li CM; Lu H; Wu HX; Qiu HX; Qian SX; Xu W; Li JY; Chen LJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1511-4. PubMed ID: 21176361
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma].
Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH
Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132
[TBL] [Abstract][Full Text] [Related]
16. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens.
Roussou M; Kastritis E; Migkou M; Psimenou E; Grapsa I; Matsouka C; Barmparousi D; Terpos E; Dimopoulos MA
Leuk Lymphoma; 2008 May; 49(5):890-5. PubMed ID: 18464107
[TBL] [Abstract][Full Text] [Related]
17. [Bortezomib combined with other drugs for treating 60 cases of multiple myeloma].
Zhong YP; Chen SL; Li X; Hu Y; Zhang JJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):214-7. PubMed ID: 19236782
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.
Quach H; Horvath N; Cannell P; Mikhael JR; Butcher BE; Prince HM
Intern Med J; 2009 May; 39(5):290-5. PubMed ID: 19371392
[TBL] [Abstract][Full Text] [Related]
19. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
20. Current treatments for renal failure due to multiple myeloma.
Kastritis E; Terpos E; Dimopoulos MA
Expert Opin Pharmacother; 2013 Aug; 14(11):1477-95. PubMed ID: 23705905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
